TrendRadars > News > Kronos and Genentech ink $20M cancer discovery pact
Kronos and Genentech ink M cancer discovery pact
Kronos and Genentech ink $20M cancer discovery pact,Kronos Bio and Roche's Genentech announced a drug discovery deal to hunt for and develop small molecule drugs aimed at transcription factors that can drive the proliferation of cancer. Under the two-program agreement, Kronos will get $20 million upfront, plus as much as $554 million in developmental and commercial milestone

Kronos and Genentech ink $20M cancer discovery pact

Kronos Bio and Roche’s Genentech announced a drug discovery deal to hunt for and develop small molecule drugs aimed at transcription factors that can drive the proliferation of cancer. Under the two-program agreement, Kronos will get $20 million upfront, plus as much as $554 million in developmental and commercial milestone